A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of met

被引:98
作者
Basilico, Cristina [1 ]
Arnesano, Addolorata [1 ]
Galluzzo, Maria [1 ]
Comoglio, Paolo M. [1 ]
Michieli, Paolo [1 ]
机构
[1] Univ Turin, Sch Med, Div Mol Oncol, Inst Canc Res & Treatment, I-10060 Turin, Italy
关键词
D O I
10.1074/jbc.M800727200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Hepatocyte growth factor (HGF) and its high affinity receptor, the tyrosine kinase Met, play a key role in embryo development and tumor invasion. Both HGF and Met are established targets for cancer therapy. However, the mechanism of their interaction is complex and remains elusive. HGF is secreted as a monomeric precursor (pro-HGF) that binds to but does not activate Met. Mature HGF is a alpha/beta heterodimer containing a high affinity Met-binding site in the alpha-chain (HGF-alpha) and a low affinity Met-binding site in the alpha-chain (HGF-alpha). The extracellular portion of Met contains a semaphorin (Sema) domain, a cysteine-rich hinge (plexin-semaphorin-integrin), and four immunoglobulin-like domains ( immunoglobulin-like regions in plexins and transcription factors (IPT) 1-4). HGF-beta binds to Sema through a low affinity contact. The domain of Met responsible for high affinity binding to HGF-alpha has not been identified yet. Here we show that this long sought after binding site lies in the immunoglobulin-like region of Met and more precisely in IPT 3 and 4. We also show that IPT 3 and 4 are sufficient to transmit the signal for kinase activation to the cytoplasm, although the lack of Sema makes the receptor equally sensitive to mature HGF and pro-HGF. Finally, we provide evidence that soluble Met-derived proteins containing either the low affinity or high affinity HGF-binding site antagonize HGF-induced invasive growth both in vitro and in xenografts. These data suggest that the immunoglobulin-like region of Met cooperates with the Sema domain in binding to HGF and in controlling Met kinase activity. Although the IPT-HGF-alpha interaction provides binding strength, the Sema-HGF-beta contact confers selective sensitivity to the active form of the ligand.
引用
收藏
页码:21267 / 21277
页数:11
相关论文
共 53 条
[1]   The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants [J].
Berthou, S ;
Aebersold, DM ;
Schmidt, LS ;
Stroka, D ;
Heigl, C ;
Streit, B ;
Stalder, D ;
Gruber, G ;
Liang, CX ;
Howlett, AR ;
Candinas, D ;
Greiner, RH ;
Lipson, KE ;
Zimmer, Y .
ONCOGENE, 2004, 23 (31) :5387-5393
[2]   Met, metastasis, motility and more [J].
Birchmeier, C ;
Birchmeier, W ;
Gherardi, E ;
Vande Woude, GF .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2003, 4 (12) :915-925
[3]   ESSENTIAL ROLE FOR THE C-MET RECEPTOR IN THE MIGRATION OF MYOGENIC PRECURSOR CELLS INTO THE LIMB BUD [J].
BLADT, F ;
RIETHMACHER, D ;
ISENMANN, S ;
AGUZZI, A ;
BIRCHMEIER, C .
NATURE, 1995, 376 (6543) :768-771
[4]   Domains in plexins: links to integrins and transcription factors [J].
Bork, P ;
Doerks, T ;
Springer, TA ;
Snel, B .
TRENDS IN BIOCHEMICAL SCIENCES, 1999, 24 (07) :261-263
[5]   Met provides essential signals for liver regeneration [J].
Borowiak, M ;
Garratt, AN ;
Wüstefeld, T ;
Strehle, M ;
Trautwein, C ;
Birchmeier, C .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (29) :10608-10613
[6]   IDENTIFICATION OF THE HEPATOCYTE GROWTH-FACTOR RECEPTOR AS THE C-MET PROTOONCOGENE PRODUCT [J].
BOTTARO, DP ;
RUBIN, JS ;
FALETTO, DL ;
CHAN, AML ;
KMIECIK, TE ;
VANDEWOUDE, GF ;
AARONSON, SA .
SCIENCE, 1991, 251 (4995) :802-804
[7]   Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors [J].
Burgess, T ;
Coxon, A ;
Meyer, S ;
Sun, J ;
Rex, K ;
Tsuruda, T ;
Chen, Q ;
Ho, SY ;
Li, L ;
Kaufman, S ;
McDorman, K ;
Cattley, RC ;
Sun, JL ;
Elliott, G ;
Zhang, K ;
Feng, X ;
Jia, XC ;
Green, L ;
Radinsky, R ;
Kendall, R .
CANCER RESEARCH, 2006, 66 (03) :1721-1729
[8]   HEPATOCYTE GROWTH-FACTOR IS A POTENT ANGIOGENIC FACTOR WHICH STIMULATES ENDOTHELIAL-CELL MOTILITY AND GROWTH [J].
BUSSOLINO, F ;
DIRENZO, MF ;
ZICHE, M ;
BOCCHIETTO, E ;
OLIVERO, M ;
NALDINI, L ;
GAUDINO, G ;
TAMAGNONE, L ;
COFFER, A ;
COMOGLIO, PM .
JOURNAL OF CELL BIOLOGY, 1992, 119 (03) :629-641
[9]   Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models [J].
Cao, B ;
Su, YL ;
Oskarsson, M ;
Zhao, P ;
Kort, EJ ;
Fisher, RJ ;
Wang, LM ;
Vande Woude, GF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (13) :7443-7448
[10]   c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention [J].
Christensen, JG ;
Burrows, J ;
Salgia, R .
CANCER LETTERS, 2005, 225 (01) :1-26